Despite medical advances, unmet patient needs are still a reality, as many treatments do not optimally improve patients’ lives, often due to efficacy, safety and/or tolerability issues that potentially lead to suboptimal clinical outcomes. TransCon (transient conjugation) technologies address these unmet needs through the creation of new and innovative therapies. TransCon molecules have three components: a parent therapeutic with well understood biology, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the parent therapeutic is shielded from clearance; when injected, physiologic pH and temperature initiate its predictable release through autocleavage of the TransCon Linker. Because the parent therapeutic is unmodified, its original mode of action is preserved. TransCon can be applied to peptides, proteins and small molecules in multiple therapeutic areas, either systemically or locally. One example is TransCon Growth Hormone (hGH), a once-weekly, long-acting recombinant hGH (somatropin). TransCon hGH, based on known pharmacology, is designed to release unmodified hGH at a predictable rate over one week. TransCon hGH was selected based on a unique algorithm for product innovation, and a comprehensive development program in pediatric subjects with growth hormone deficiency was implemented. This program included 9 clinical trials, including three phase 3: heiGHt, fliGHt and enliGHten. More than 400 subjects have participated. An auto-injector with connectivity capability was developed to monitor treatment adherence. The phase 3 heiGHt and fliGHt Trials confirmed earlier results, demonstrating TransCon hGH as a promising alternative to daily therapy. Additionally, in heiGHt, once-weekly TransCon hGH showed comparable safety and tolerability to daily hGH, with a significantly greater increase in annualized height velocity. Conclusion: TransCon technologies have been clinically validated by the TransCon hGH program and hold promise as a new approach to addressing unmet medical needs that may reduce the risks of traditional drug development.